Novel TB Vaccine Candidates in The Art and Science of Tuberculosis Vaccine Development. Oxford University Press. Mohd Nor M, Acosta A and Sarmiento ME (Eds).

BIGI F; CATALDI A ; NORAZMI MOHD NOR, ; MARIA ELENA SARMIENTO; ARMANDO ACOSTA

Oxford University Press.

Año: 2010 p. 390

CHAPTER 11   Strategies for New Generation Vaccine Development     Angel Cataldi, Fabiana Bigi, Norazmi Mohd Nor, Maria Elena Sarmiento,  and Armando Acosta       Various chapters in this book alluded to the inability of BCG to confer protection against adult pulmonary TB and its failure to block the transmission of the disease. In addition, there are problems associated with latent TB and the appearance of MDR strains. The HIV-TB coinfection has further complicated the problem, and hence there is an urgent need to develop new generation vaccines against TB.   Currently, with the advent of new technologies, including those in genomics, proteomics, bioinformatics, nanotechnology, new adjuvants/formulations, and whole genome sequence of MTB and other mycobacteria, many different strategies are being used to develop new candidate vaccines against TB. These new technological approaches have enhanced the exploitation of new knowledge related to the MTB mechanisms of infection and virulence as well as host immune mechanisms of defense against the bacteria.   In various chapters of the book, new TB vaccines are described from a functional point of view. This chapter provides a brief overview of the different candidate antigens and the delivery strategies employed (Table 11.1), experimental strategies that are being used (Table 11.2), mutant live vaccines under investigation (Table 11.3), adjuvants used (Table 11.4), routes of administration employed (Table 11.5), and mycobacterial glycolipides (Table 11.6) for new generation TB vaccine development. The reader is recommended to refer to the listed literature to obtain more detailed information on each of these topics.